Sotera Health (SHC) Stock Forecast & Price Target

Sotera Health is projected to experience robust adjusted EBITDA growth, with an expected compound annual growth rate of 6.7% from $589 million in 2025 to $716 million in 2028, indicating a slight improvement in margins over this period. The company's revenue growth guidance remains strong at 4.5-6%, with notable enhancements in the Sterigenics segment contributing to a forecasted margin expansion of around 90 basis points through 2028. Additionally, the increasing share of pharmaceuticals in the revenue mix and initial success in the cross-selling strategy are driving higher customer satisfaction and reinforcing a positive outlook for future profitability.

Sotera Health's stock faces a negative outlook primarily due to a significant decline in adjusted EBITDA margins, which fell by approximately 180 basis points from 51.7% in 2021 to 49.9% in 2024, largely driven by inflation, overstaffing, and a problematic revenue mix within its Nelson Labs segment. The company has struggled to maintain its prior higher-margin revenue streams and anticipates a mid-single-digit decline in sales for the Nelson Labs segment in 2025 due to a lack of FDA activity and a shift toward lower-margin services. Furthermore, despite modest organic revenue growth averaging 9.0% from 2021 to 2022, recent top-line pressures from customer supply chain challenges and declining testing volumes have hindered overall performance, contributing to underperformance against the S&P 500 since its IPO.